Learn more about our Diagnostics work.
Today, AdvaMedDx®, a division of AdvaMed® representing manufacturers of innovative in vitro diagnostic tests, sent a letter urging Congressional leaders to prioritize the reauthorization of the President’s Emergency Plan for…
AdvaMed, The Medtech Association®, released the following statement from President and CEO Scott Whitaker and Zach Rothstein, Executive Director of AdvaMedDx®, on FDA’s recently proposed LDT rule.
Today, AdvaMed, The Medtech Association®, released updated reports, in collaboration with Deloitte on frameworks for the comprehensive assessment of medical technologies and diagnostic tests. These seminal reports had been developed…
AdvaMed, The Medtech Association®, joined members the Global Medical Technology Alliance (GMTA) to welcome the recently released World Health Assembly (WHA) resolution on Strengthening Diagnostic Capacity.
This Women’s Health Month, AdvaMed® is highlighting new developments in breast cancer screening.
On March 29, AdvaMed® responded to the Senate HELP Committee’s request for information on policy priorities for the reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA).
Today, AdvaMed, The Medtech Association®, released the following statement from President and CEO Scott Whitaker on the introduction of the bipartisan Verifying Accurate, Leading-edge IVCT Development (VALID) Act. Introduced in…
Today, AdvaMed, The Medtech Association®, applauded the introduction in the House and Senate of the bipartisan Saving Access to Laboratory Services Act (SALSA) by Senators Sherrod Brown (D-OH) and Thom…
Today, AdvaMed, The Medtech Association®, released the following statement from President and CEO Scott Whitaker on the introduction of the bipartisan Ensuring Patient Access to Critical Breakthrough Products Act. The…
AdvaMedDx®, a division of AdvaMed® representing more than 75 manufacturers of innovative in vitro diagnostic (IVD) tests and technologies in the U.S. and abroad, announced today that Thierry Bernard, CEO…